At Cell Therapy Sciences we harness the regenerative properties of mesenchymal stem cells to prepare clinical therapies for dogs and horses. Based on our own research, we have optimised these therapies to ensure you receive the very best cells for your patients.

From a small piece of an animal's own tissue, many millions of regenerative cells can be grown by culture-expansion in our specialised VMD-authorised laboratory. We have developed our own, evidence-based procedures for harvest, implantation and transportation, which are simple and practical for vets - and ensure the highest possible standards of safety and quality for pets.

The Evidence Base?

Culture-expanded, mesenchymal stem cells (MSCs) have been used to treat lameness, pain and degenerative joint problems in dogs and horses for more than 10 years. The most recent clinical evidence includes a number of significant, well controlled and large clinical investigations into canine OA (e.g. Shah et al 2018; Harman et al 2016) with authors reporting that MSCs can not only reduce pain and inflammation, but also improve quality of life and enhance tissue repair. The World Small Animal Veterinary Association recognises stem cells in their pain management protocol and include stem cell injectionsfor DJD in dogs and cats in their Pain Council Guidelines.

Why use our culture-expanded stem cells?

We are the most experienced companion animal stem cell laboratory in the UK, having prepared > 2,000 stem cell treatments for intra-articular and intravenous use in client-owned dogs and cats.

We conduct our own laboratory research and have ongoing scientific collaborations with leading stem cell centres, including University College London, Stem Cells Scotland and Coventry University.

Four clinical investigations to date in moderate to severe canine OA have reported significant reductions in pain and improvements in functional mobility following intra-articular injections using our stem cell preparations. These include the first reported study to use two validated arthritis questionnaires to evaluate clinical outcomes in OA (Armitage et al 2018).

Our VMD-authorised cryogenic storage and transport system maximises stem cell quality and viability at point of care and has been shown to be superior to shipping at ambient temperatures.

See the original post here:
Cell Therapy Sciences